Back |
home / stock / cyad / cyad message board
Subject | By | Source | When |
---|---|---|---|
OK We'll see how RHOI does when the | jj373 | investorshub | 09/01/2006 8:42:08 PM |
Even for what? You already know what's | skeptic0 | investorshub | 09/01/2006 6:49:52 PM |
I owed you that - now we are | jj373 | investorshub | 09/01/2006 5:20:45 PM |
Where the pumps. Just your bashing to | skeptic0 | investorshub | 09/01/2006 4:57:02 PM |
They are still pumping this POS after the | jj373 | investorshub | 09/01/2006 7:37:58 AM |
I wonder if Walt Tatum knew about the | jj373 | investorshub | 08/30/2006 10:43:20 PM |
So, I guess this won't trade now for | skeptic0 | investorshub | 08/30/2006 2:59:49 PM |
No. I went back and reviewed the | skeptic0 | investorshub | 08/30/2006 6:50:48 AM |
I predict CYAD will open @ .90-.95 tomorrow; | flaflyersfan | investorshub | 08/30/2006 3:05:59 AM |
Where did I predict .10 ? You are | Mr. Bill | investorshub | 08/29/2006 11:06:52 PM |
I really do not understand the point that | jj373 | investorshub | 08/29/2006 11:04:42 PM |
EZ is the master-he makes $ even on | ground_fog | investorshub | 08/29/2006 7:41:39 PM |
It wasn't mentioned in the Def 14C was | ballyhooo | investorshub | 08/29/2006 6:03:54 PM |
wow, dodged that bullet. | was pennytrader | investorshub | 08/29/2006 6:02:41 PM |
13:28 08/30/2006 CYAD CyberAds, Inc. | ballyhooo | investorshub | 08/29/2006 5:53:42 PM |
Geez, follow the trail it is OBVIOUS | Mr. Bill | investorshub | 08/29/2006 5:11:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Celyad SA Company Name:
CYAD Stock Symbol:
NASDAQ Market:
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced...
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Bid Price No...
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letterȁ...